Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

(ATLANTA, December 8, 2012) The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

CLL is a blood cancer that causes abnormal white blood cells called lymphocytes to accumulate in the blood, bone marrow, and in the lymph nodes or other organs, causing these organs to enlarge. Approximately 15,000 Americans are diagnosed with CLL every year; nearly 70 percent of those affected are 65 and older. , For some patients with slower growing disease, physicians employ "watch and wait" strategies to minimize unnecessary treatment. However, patients with high-risk features such as rapidly progressing disease require prompt treatment to manage symptoms and reduce organ damage.

Ibrutinib is a specialized anti-cancer therapy that targets the Bruton's tyrosine kinase (BTK, an enzyme important in the development of CLL). As an inhibitor of BTK, ibrutinib selectively targets leukemia cells, promoting their death and preventing them from growing while leaving normal cells unharmed. Studies suggest this design allows the drug to more effectively treat the disease, with encouraging early results in harder-to-treat patient groups such as elderly untreated patients and those whose disease has become resistant to other therapies or those who have experienced disease recurrence after receiving other therapies. Two studies will present efficacy and safety results testing the compound alone and in combination with other currently used therapies for CLL.

"The evidence collected to date on ibrutinib demonstrates that it may have the potential to improve long-term prognosis for patients who are not sensitive to standard treatment," said Claire E. Dearden, MD, moderator of the press conf
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 The Deptford ... have launched a partnership designed to improve the ... congestive heart failure (CHF) patients in the South ... and Lourdes Cardiology team will help CHF patients ... protocols. This partnership pairs the Cardiac Recovery program ...
(Date:11/26/2014)... 26, 2014 German scientists say carbon-based ... can cause mesothelioma that looks and acts similar to ... article on the research. Click here to read ... for Toxicology and Experimental Medicine in Hannover injected 500 ... of the rats eventually developed mesothelioma , how ...
(Date:11/26/2014)... Loffler Companies has been selected as a 2014 ... information and news publication for resellers of imaging technology, ... Loffler has earned this prestigious award and the seventh ... honor the best and the brightest in the imaging ... chosen for their innovative marketing and sales programs, community ...
(Date:11/26/2014)... Howell, NJ (PRWEB) November 26, 2014 ... issues,” and Florida-based SeniorNet, a nonprofit organization providing the ... have teamed up to help seniors navigate the rough ... will focus on educating seniors on the topic of ... through the somewhat complicated process of applying for this ...
(Date:11/26/2014)... Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with ... sales(at)researchmoz(dot)us , Researchmoz.us announces a new research report ... deep study of the report on the diabetes topic ... The global glucose monitoring market has a growth rate ... diabetics in the world. Their numbers have prompted the ...
Breaking Medicine News(10 mins):Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3
... maximizes UHPLC or HPLC productivity via seamless hardware/software ... new and existing Corona detector customersCHELMSFORD, Mass., May ... UHPLC detector with a Waters ACQUITY UPLC(R) or ... new Empower 2/Corona detector instrument-control software driver. ESA ...
... Senate health care reform leaders must not override state ... week, a move long-supported by insurers and the Bush ... president and senators. The hard-fought state laws enacted in ... made necessary because Congress failed to enact Patients, Bill ...
... Co., Inc., (NYSE Amex: TPI ), a ... in Chengdu, China, today,announced that management will hold a ... 11:00 a.m. EDT on Friday, May 15, 2009. Financial,results ... market closes. , Interested parties ...
... Colo., May 11 Bill Carlson, vice president, marketing ... & Demand Chain Executive magazine,s 2009 Pros to ... supply chain in healthcare. With more than 20 years ... the challenges of today,s economy, in which supply chain ...
... HealthCentral ( www.HealthCentral.com ... health and wellness experiences, today announced a new ... the number one online resource for breast cancer ... will arrange for high-quality, relevant sponsorship programs to ...
... undergoing a radical prostatectomy can greatly increase their chances ... Henry Ford Hospital. , Results from the study done ... procedure improves the 5-, 10-, 15- and 20-year survival ... such as radiotherapy or watchful waiting. , "When given ...
Cached Medicine News:Health News:ESA's Corona(R) Family of HPLC Detectors, Including the New Corona ultra(TM), Can Now be Controlled by Waters Empower(R) 2 Chromatography Software 2Health News:President Obama, Sens. Kennedy & Baucus: Don't Buy Insurer 'Compromise' for Bush-era Plan to Gut State Consumer Protection Laws 2Health News:President Obama, Sens. Kennedy & Baucus: Don't Buy Insurer 'Compromise' for Bush-era Plan to Gut State Consumer Protection Laws 3Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Third Quarter Earnings Conference Call on Friday, May 15, 2009 at 11:00 a.m. EDT 2Health News:GHX Vice President Bill Carlson Named to Supply & Demand Chain Executive's 2009 Pros to Know List 2Health News:HealthCentral.com Collaborates With BreastCancer.org, Providing Quality Awareness Sponsorships to #1 Breast Cancer Resource Online 2Health News:Surgery improves survival for prostate cancer patients younger than 50 2
(Date:11/26/2014)... November 26, 2014 Investor-Edge has initiated ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ), ... (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... be accessed at: http://investor-edge.com/register . On Tuesday, ... 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to ...
(Date:11/26/2014)... Pa. , Nov. 26, 2014 ... to the development of innovative transdermal synthetic cannabinoid treatments, ... Piper Jaffray 26th Annual Healthcare Conference 2014. The conference ... New York Palace in New York ... will present at 4:50 pm on Tuesday, December 2. ...
(Date:11/26/2014)... and LONDON , Nov. ... market intelligence, MarketResearch.com is pleased to announce the distribution ... Consultancy focusing on the active pharmaceutical ingredient (API) market. ... http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s newest ... Forecast to 2020 , IQ4I analysts ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
... Glucose without ... Trial Expected to Begin upon Ethics Approval with Results due in Q1 ... ... Phosphagenics,Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today,announced the successful completion of ...
... dysfunction after,surgery to remove the prostate (radical prostatectomy) has ... over time.,But it can take as long as two ... to have an erection without the aid of drugs ... according to an article in the latest issue,of Perspectives ...
Cached Medicine Technology:Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 2Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 3'Use it or Lose it': A New Theory About Preserving Erectile Function After Prostate Surgery 2
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
Rad-5 signal extraction pulse oximeter™...
... The Avant® 4000 System with ... wired connections while ensuring reliable and ... all in a small package. The ... data to a small tabletop display, ...
Weighing just two ounces, this durable, self-contained unit delivers an accurate pulse rate and bloodoximetry in just seconds....
Medicine Products: